These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. He J; Gu L; Zhang H; Zhou M Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876 [TBL] [Abstract][Full Text] [Related]
5. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029 [TBL] [Abstract][Full Text] [Related]
6. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746 [TBL] [Abstract][Full Text] [Related]
7. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma. Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940 [TBL] [Abstract][Full Text] [Related]
8. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167 [TBL] [Abstract][Full Text] [Related]
9. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458 [TBL] [Abstract][Full Text] [Related]
10. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782 [TBL] [Abstract][Full Text] [Related]
11. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228 [TBL] [Abstract][Full Text] [Related]
12. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. Gu L; Zhang H; He J; Li J; Huang M; Zhou M Oncogene; 2012 Mar; 31(11):1342-53. PubMed ID: 21822304 [TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000 [TBL] [Abstract][Full Text] [Related]
14. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398 [TBL] [Abstract][Full Text] [Related]
15. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359 [TBL] [Abstract][Full Text] [Related]
16. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771 [TBL] [Abstract][Full Text] [Related]
17. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas. Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720 [TBL] [Abstract][Full Text] [Related]
18. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes. Kumps C; Fieuw A; Mestdagh P; Menten B; Lefever S; Pattyn F; De Brouwer S; Sante T; Schulte JH; Schramm A; Van Roy N; Van Maerken T; Noguera R; Combaret V; Devalck C; Westermann F; Laureys G; Eggert A; Vandesompele J; De Preter K; Speleman F PLoS One; 2013; 8(1):e52321. PubMed ID: 23308108 [TBL] [Abstract][Full Text] [Related]
19. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637 [TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line. Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]